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Abstract
Monoamine oxidase (MAO) inhibitors ameliorate contractile function in diabetic animals, but the mechanisms remain
unknown. Equally elusive is the interplay between the cardiomyocyte alterations induced by hyperglycemia and the
accompanying inflammation. Here we show that exposure of primary cardiomyocytes to high glucose and pro-inflammatory
stimuli leads to MAO-dependent increase in reactive oxygen species that causes permeability transition pore opening and
mitochondrial dysfunction. These events occur upstream of endoplasmic reticulum (ER) stress and are abolished by the
MAO inhibitor pargyline, highlighting the role of these flavoenzymes in the ER/mitochondria cross-talk. In vivo,
streptozotocin administration to mice induced oxidative changes and ER stress in the heart, events that were abolished by
pargyline. Moreover, MAO inhibition prevented both mast cell degranulation and altered collagen deposition, thereby
normalizing diastolic function. Taken together, these results elucidate the mechanisms underlying MAO-induced damage in
diabetic cardiomyopathy and provide novel evidence for the role of MAOs in inflammation and inter-organelle
communication. MAO inhibitors may be considered as a therapeutic option for diabetic complications as well as for other
disorders in which mast cell degranulation is a dominant phenomenon.
Introduction
Cardiovascular complications account for the high morbidity
and mortality in patients with type 1 and type 2 diabetes (T1D,
T2D) [1]. Diabetic cardiomyopathy (DCM) is a distinct
myocardial disease, characterized by structural changes in the
heart and diastolic/systolic dysfunction. Several factors,
including reactive oxygen species (ROS) formation and
mitochondrial dysfunction, contribute to hyperglycemia-
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Fig. 1 Effects of MAO inhibition on HG and pro-inflammatory cyto-
kine IL-1β induced ROS formation in NRVMs. ROS formation was
measured with genetically encoded H2O2 sensitive probe HyPer tar-
geted either to mitochondria (a, b) or to the cytosol (d, e) upon
NRVMs treatment with NG or HG in the absence or presence of IL-1β,
and with or without pargyline. Effects of HM, as osmotic control, were
assessed on mitochondrial (c) and cytosolic (f) H2O2 formation. MAO-
A expression was assessed at different time-points following control or
MAO-A siRNA treatment (g, h). ROS formation in control or MAO-A
siRNA-treated cells was assessed upon treatment with NG or HG in
the absence or presence of IL-1β (i). Approximately 100 cells were
analyzed per condition in each experiment and all the experiments
were performed at least three times. Data are expressed as mean±
SEM. Two-way ANOVA test followed by post hoc Tukey’s (b and i)
or Dunn’s (e) multiple comparison test (*p< 0.05 vs NG vehicle, #p<
0.05 vs HG vehicle and §p< 0.05 vs HG-IL1β)
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induced changes and to the etiology of DCM [2–7]. Indeed,
respiratory chain-generated superoxide and p66Shc lead to
increased ROS levels characterizing mitochondria isolated
from diabetic hearts or cardiomyocytes incubated with high
glucose (HG) [8–12].
More recently, monoamine oxidases (MAOs) have been
shown to play a major role in the oxidative stress and
development of several cardiovascular pathologies, including
DCM [13–16]. These flavoenzymes, localized at the outer
mitochondrial membrane, exist as two isoenzymes (MAO-A
and -B) and present unique features among ROS sources. The
mechanism of catalysis has been elucidated and the crystal
structure solved [17, 18]. During substrate degradation MAOs
generate H2O2, aldehydes and ammonia [14], thus repre-
senting a source of ROS in the heart, particularly under stress
conditions. In addition, MAOs utilize specific substrates
important for cardiovascular pathophysiology, such as cate-
cholamines and serotonin. Nevertheless, the mechanisms of
Fig. 2 Effects of MAO inhibition on ROS formation and ΔΨm in
cardiac myocytes exposed to HG and/or IL-1β. ROS formation was
assessed with the fluorescent dye MTR in adult cardiomyocytes treated
with NG or HG in the absence or presence of IL-1β, and with or
without pargyline (a, b). Effects of the osmotic control HM on ROS
formation (c, f). ΔΨm was measured in adult cardiomyocytes with the
fluorescent dye TMRM in the same conditions as above (d–f). In
neonatal cardiomyocytes, ΔΨm was measured following 48 h treatment
with NG or HG in the absence or presence of IL-1β (g). Kinetic
measurements were performed to follow TMRM fluorescence intensity
following additions of oligomycin and FCCP, indicated by arrows (h).
Approximately 100 cells were analyzed per condition in each
experiment and all the experiments were performed three times. Data
are expressed as mean± SEM. Two-way ANOVA test followed by
post hoc Tukey’s (b) or Dunn’s (e) multiple comparison test (*p< 0.05
vs NG vehicle, #p< 0.05 vs HG and §p< 0.05 vs HG+ IL-1β vehicle)
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MAO-induced cardiac damage are incompletely understood,
especially in the context of DCM.
Endoplasmic reticulum (ER) stress is another key
determinant in cardiac physiology and pathology [19, 20].
Impairment in ER homeostasis results in ER stress, accu-
mulation of unfolded proteins and activation of complex
signaling pathways collectively termed the unfolded protein
response (UPR). If ER stress is severe or prolonged, the
UPR may stimulate apoptosis, a significant feature of
hypoxia, ischemia/reperfusion injury and DCM [19, 21].
Notably, ER and mitochondria are structurally and func-
tionally connected [22–26]. Yet, whether mitochondrial
ROS formation and dysfunction are upstream of ER stress
or vice-versa is not known.
Inflammation exacerbates cellular responses to HG and,
along with excessive ROS formation, is closely associated
with tissue repair, scar formation, and fibrosis [27–29].
Cardiac resident mast cells hold secretory granules con-
taining histamine, proteases and a variety of cytokines,
growth factors, and other biologically active mediators
capable of mediating tissue remodeling. Indeed, cardiac
mast cell activation may contribute to fibrotic remodeling of
the cardiac tissue [30, 31]. Although the pathologic
importance of mast cells is becoming increasingly clear,
triggers leading to their activation and degranulation have
not been completely elucidated.
Despite the plethora of evidence that ROS formation,
mitochondrial dysfunction and ER stress contribute to the
development of DCM, the precise interplay between these
events remains elusive. Here, we tested the hypothesis that
MAO-induced ROS formation may represent the common
denominator and investigated whether: (i) MAOs are
involved in mitochondrial ROS formation and dysfunction
triggered by hyperglycemia and inflammation; (ii) MAO-
dependent mitochondrial derangements are upstream of ER
stress occurring in the diabetic heart; (iii) MAO activity is
related to cardiac fibrosis through mechanisms involving
other cardiac cell types, such as mast cell degranulation.
Results
MAOs account for ROS formation in isolated
cardiomyocytes exposed to HG and pro-
inflammatory cytokine IL-1β
IL-1β, a pro-inflammatory cytokine and a regulator of the
inflammatory response, is elevated in T1D and T2D [32]. Thus,
to better mimic diabetic conditions in vitro, neonatal rat ven-
tricular myocytes (NRVMs) were treated with HG alone or in
combination with IL-1β. HG led to a significant increase in
both mitochondrial (Fig. 1a, b) and cytosolic H2O2 formation
after 48 h (Fig. 1d, e). This rise was not due to hyperosmolarity,
since identical concentrations of mannitol did not show any
changes in ROS levels (Fig. 1c, f, Supplementary Figures S1A
and B). Moreover, IL-1β alone did not exert any effect on
mitochondrial ROS formation at any of the time-points
examined (Supplementary Figures 1C and D). Interestingly,
combination of HG and IL-1β led to a further dramatic increase
in H2O2 production when compared to HG or IL-1β treatment
alone, indicating a synergistic effect of these stimuli in inducing
ROS formation. Administration of pargyline, an inhibitor of
both MAO isoforms, normalized ROS levels in these condi-
tions (Fig. 1a–f), suggesting that HG and IL-1β induce ROS
formation in a MAO-dependent manner. These results were
confirmed using siRNA against MAO-A, the major MAO
isoform expressed in the NRVMs (Supplementary Figures S2A
and B). After 96 h of siRNA treatment, MAO-A protein
expression was reduced by ~80% (Fig. 1g, h). HG and IL-1β
were unable to induce an increase in ROS formation in these
siRNA-treated cells, unequivocally demonstrating the con-
tribution of MAO to this process (Fig. 1i).
To increase the translational value of the findings obtained
in neonatal cells, we tested whether the same outcome holds
true in the adult mouse cardiomyocytes. HG showed a more
prominent effect in adult cardiomyocytes, leading to a ~2-fold
increase in ROS generation after only 2 h of incubation
(Fig. 2a, b). Again, this effect was not due to changes in
osmotic pressure (Fig. 2c) or MAO protein abundance
(Supplementary Figure S3). However, unlike NRVMs, no
further increase in oxidative stress was evident after HG+IL-
1β co-treatment. Pargyline treatment reduced ROS formation
in both conditions, thus confirming that MAO plays a pivotal
role in HG- and IL-1β-induced oxidative stress.
Since mitochondrial ROS have been described as inflam-
matory triggers [33], we investigated this link also in cardi-
omyocytes. Strong upregulation of NLRP3 and ASC upon
lipopolysaccharide treatment confirmed that NRVMs are
capable of activating NLRP3 inflammasome (Supplementary
Figure S4A). Next, we assessed inflammasome activation in
NRVMs treated with HG and/or IL-1β and observed an
upregulation of NLRP3 only in cells treated either with IL-1β
alone or with the combination of HG and IL-1β (Supple-
mentary Figure 4B). This increase in NLRP3 expression was
not affected in cells treated with pargyline, suggesting that
MAO activity does not impact on inflammasome activation.
MAO-dependent ROS generation impairs
mitochondrial function in cardiomyocytes exposed
to HG and IL-1β
Next, we investigated whether increased ROS emission due
to HG and IL-1β, alone or in combination, is sufficient to
alter mitochondrial function in cardiomyocytes. We found
that mitochondrial membrane potential (ΔΨm) was mark-
edly reduced in adult cardiomyocytes already after 5 h of
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HG treatment (Fig. 2d–f). This effect was further exacer-
bated when HG was combined with IL-1β. Of note, there
was no change in ΔΨm after 2 h of treatment with HG or
HG+IL-1β (Supplementary Figure S5), suggesting that
MAO-dependent ROS formation is upstream of mitochon-
drial (dys)function. Unlike adult cardiomyocytes, NRVMs
exposed to HG did not show any changes in ΔΨm even after
48 h (Fig. 2g). These findings prompted us to examine
whether HG induces latent mitochondrial dysfunction in
NRVMs. It is well established that ATP synthase can mask
the loss of ΔΨm by working in a reverse mode [34]. Thus, to
assess whether ATP synthase activity was compensating for
the dysfunctional respiratory chain in these cells, we mon-
itored tetramethylrhodamine methyl ester (TMRM) fluor-
escence intensity in the presence of the ATP synthase
inhibitor oligomycin. Normal glucose (NG) or high man-
nitol (HM) treated cells maintained ΔΨm for up to 1 h
following oligomycin administration (Fig. 2h). On the other
hand, TMRM fluorescence intensity started to drop imme-
diately in HG-treated cells upon oligomycin addition.
Hence, HG induces mitochondrial dysfunction in NRVMs,
but in order to maintain ΔΨm, these cells start to hydrolyze
glycolytically synthesized ATP by reversing the activity of
the ATP synthase. Pre-treatment with pargyline maintained
ΔΨm in both neonatal and adult cardiomyocytes, indicating
that MAO-generated ROS trigger mitochondrial dysfunc-
tion in cardiomyocytes treated with HG and IL-1β.
MAO-generated ROS trigger mitochondrial
depolarization through permeability transition pore
opening
To investigate the mechanism underlying mitochondrial
dysfunction induced by MAO-generated ROS, we assessed
Fig. 3 Mitochondrial respiration
and PTP opening in
cardiomyocytes exposed to HG
and/or IL-1β. Oxygen
consumption at baseline (S4)
and following addition of ADP
(S3) was measured in
permeabilized neonatal (a, n=
3) or adult cardiomyocytes,
using either glutamate/malate (b,
n= 4) or succinate in the
presence of rotenone (c, n= 3)
as substrates. The effect of the
PTP inhibitor CsA on ΔΨm was
assessed in neonatal
cardiomyocytes (d) upon 48 h
treatment with NG or HG and
IL-1β in presence of oligomycin.
Adult cardiomyocytes (e) were
treated with NG or HG and IL-
1β for 5 h, in the presence and
absence of CsA. For TMRM
experiments, between 50 and
100 cells were analyzed per
condition in each experiment
and all the experiments were
performed at least three times.
Data are expressed as mean±
SEM. Two-way ANOVA test
followed by post hoc Dunn’s
multiple comparison test (*p<
0.005 vs NG, #p< 0.05 vs NG
+ IL-1β, §p< 0.005 vs
respective group treated with
vehicle)
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the function of the respiratory chain by measuring oxygen
consumption in permeabilized cells. Mitochondrial respiration
was not impaired in any of the groups examined either in
NRVMs (Fig. 3a) or in the adult cardiomyocytes (Fig. 3b, c),
suggesting that the observed drop in ΔΨm was not due to
alterations of the respiratory chain complexes. Considering
that oxidative stress is a strong inducer of the permeability
transition pore (PTP) opening [35], we next hypothesized that
the loss of ΔΨm might have been caused by the opening of
the PTP. Interestingly, mitochondrial depolarization following
HG and/or IL-1β treatment was prevented when cells were
co-treated with the PTP inhibitor cyclosporin A (CsA, Fig. 3d,
e). These results suggest that MAO-dependent oxidative stress
can directly target PTP to induce its opening thereby resulting
in mitochondrial dysfunction.
MAO inhibition prevents the activation of UPR in
cardiomyocytes treated with HG and IL-1β
ER stress may be mediated by increased oxidative stress
and vice-versa [22, 36, 37]. Here we sought to determine
whether HG and IL-1β perturb ER function in a MAO-
dependent manner. Expression levels of GRP78/BiP, an ER
chaperone and a central regulator of UPR, were ~3 fold
Fig. 4 Effects of MAO inhibition on ER stress in adult cardiomyocytes
exposed to HG and/or IL-1β. Representative western blots (a) and
quantification of the protein expression of ER stress markers GRP78
(b), GADD34 (c), ATF4 (d), and phosphorylation levels of IRE1α (e)
were assessed in adult cardiomyocytes treated with HG and IL-1β with
(white) or without (black) pargyline for 48 h. Protein expression was
normalized to total protein determined by Red Ponceau staining.
Effects of the MAO inhibitor pargyline and the chemical chaperone
TUDCA on tunicamycin-induced upregulation of ER stress markers (f,
n= 3 per each group). All the experiments were performed at least
three times. Data are expressed as mean ± SEM. Two-way ANOVA
test followed by post hoc Tukey’s multiple comparison test (*p< 0.05
vs NG vehicle, #p< 0.05 vs HG and §p< 0.05 vs HG+ IL-1β vehicle,
†p< 0.005 vs respective control, ‡p< 0.005 vs Tunica)
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upregulated in the presence of HG and HG+IL1β (Fig. 4a,
b). Furthermore, the expression of growth arrest- and DNA
damage-inducible protein GADD34 (Fig. 4c) and tran-
scription factor ATF4 (Fig. 4d), two proteins downstream of
GRP78, was also significantly increased. Accordingly,
phosphorylation levels of IRE1α, an ER transmembrane
kinase, were higher as well, further confirming the activa-
tion of the UPR (Fig. 4e). Importantly, MAO inhibition
prevented the UPR activation induced by HG and IL-1β in
adult cardiomyocytes (Fig. 4a–e). Thus, the effects pro-
duced by MAO-dependent ROS formation go well beyond
mitochondria, affecting also ER homeostasis to activate the
UPR. Furthermore, excessive mitochondrial ROS formation
and dysfunction are upstream of ER stress, at least under
present experimental conditions. Next, we tested whether
MAO takes part in the cell damage triggered by well-known
Fig. 5 Characterization of LV function, oxidative and ER stress in
vehicle- and pargyline-treated STZ-mice. Representative pressure-
volume loops from control (blue, n= 6), STZ (black, n= 8), control
+ pargyline (green, n= 4) and STZ+ pargyline (red, n= 10) treated
mice (a). Ejection fraction (b) and diastolic stiffness (c) were deter-
mined in vehicle (black bars) or pargyline (white bars) treated control
and STZ mice. Levels of 4-HNE (d, e) were assessed in heart tissue
lysates from control, STZ and STZ+pargyline treated mice. Protein
levels were normalized to total protein content determined by Red
Ponceau staining (n= 5 per each group). Representative Western blot
for ER stress markers performed in heart tissue lysates from control,
STZ and STZ+pargyline treated mice (f). ATF4 (g) and GADD34 (h)
band intensities were quantified and normalized to total protein content
determined by Red Ponceau staining (n= 5 per each group). PV loop
analysis was carried out by an observer blinded to the experimental
conditions. Data are expressed as mean± SEM. Two-way ANOVA
test followed by post hoc Tukey’s multiple comparison test (*p< 0.05
vs CT vehicle, #p< 0.05 vs STZ vehicle)
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ER stressors, such as tunicamycin and thapsigargin. The
latter compounds led to severe ER stress that MAO inhi-
bition was not able to abolish (Fig. 4f, Supplementary
Figure S6A). Pargyline treatment partially reduced
tunicamycin-induced ROS formation (Supplementary Fig-
ure S6B); however, it did not prevent cell death caused by
either compound (Supplementary Figure S6C). These
results show that MAO is central to ROS-induced ER stress/
UPR activation. Accordingly, MAO inhibition effectively
prevents ER stress when UPR is activated by oxidative
stress, but not when ER stress is triggered by other redox-
independent mechanisms, such as inhibition of N-linked
glycosylation or depletion of ER Ca2+ stores.
MAO inhibition prevents diastolic dysfunction in
streptozotocin-treated mice
To investigate whether MAO contributes to the cardiac
dysfunction associated with diabetes, MAO inhibitor
pargyline was administered to streptozotocin (STZ)
treated mice. Pressure-volume (PV) relationships
revealed that STZ-mice have smaller hearts with a sig-
nificant reduction in left ventricle (LV) chamber volumes
(Fig. 5a and Table 1). STZ-mice treated with pargyline
showed an improvement in cardiac morphology, although
the differences were not statistically significant between
the two groups. Heart rate and cardiac output were similar
between groups (Table 1). We found that, although
ejection fraction (an index of systolic function) was also
unaffected in STZ-treated mice (Fig. 5b), dP/dtmax and
dP/dtmin (load-dependent indices of contractility and
relaxation) showed a trend to a decrease (Table 1). These
data suggest that, whereas systolic function is unaffected
after 12 weeks from diabetes induction, STZ mice can
still develop overt systolic impairment with time. At the
same time, there was an increase in diastolic stiffness, an
index of diastolic dysfunction, which was 4.6-fold higher
in the diabetic mice (Fig. 5c). Hence, our findings are
congruent with several clinical reports showing that
diastolic dysfunction is an early event in diabetic cardi-
omyopathy in which systolic impairment will eventually
occur at later stages [7]. Importantly, pargyline admin-
istration prevented diastolic stiffening in STZ-mice,
suggesting that MAO contributes to diastolic dysfunction
in T1D.
Oxidative stress and ER stress are reduced in STZ
hearts upon pargyline treatment
We next examined whether MAO contributes to oxidative
and ER stress in T1D in vivo. Formation of 4-
hydroxynonenal (4-HNE), an aldehyde product of lipid
peroxidation, was measured as an index of oxidative stress.
In line with our in vitro data, we found increased levels of
4-HNE in STZ hearts (Fig. 5d, e). This was accompanied by
impaired ER homeostasis as demonstrated by the induction
of UPR associated proteins ATF4 (Fig. 5f, g) and GADD34
(Fig. 5f, h). Pargyline administration to diabetic mice
Table 1 Glycemic and hemodynamic parameters measured in STZ-mice
Control (n= 6) Control+ Parg
(n= 4)
STZ (n= 8) STZ+ Parg
(n= 10)
Glucose (mmol/l) 10.20± 1.40 8.60± 0.40 32.20± 30* 32.10± 3.10*
Body weight (g) 33.10± 2.70 32.40± 2.00 25.50± 4.30 24.20± 5.30
Heart rate (bpm) 380.56± 20.42 446.59± 21.90 350.57± 16.58 343.83± 1.94
EDV (µl) 65.66± 9.43 70.50± 2.60 47.62± 3.52* 50.70± 2.87*
ESV (µl) 21.50± 4.28 27.00± 1.41 14.87± 1.74 15.30± 1.49
SV (µl) 44.16± 5.31 43.50± 2.38 32.87± 2.12* 35.20± 2.11*
EF (%) 68.01± 2.06 61.75± 2.07 69.34± 1.76 69.82± 1.88
Diastolic stiffness (1/
µl)
0.0158± 0.005 0.010± 0.004 0.069± 0.009* 0.0331± 0.007†
ESP (mmHg) 82.66± 2.39 91.63± 5.72 67.47± 5.67 76.20± 1.94
EDP (mmHg) 8.58± 1.53 5.98± 1.79 9.21± 2.20 10.32± 1.75
dP/dtmax (mmHg/s) 5487.40± 430.94 7120.29± 522.16 4101.85± 645.78 4713.28± 316.7
dP/dtmin (mmHg/s) −5930.80± 389.2 −7161.70± 804.36 −4001.3± 886.9 −4500.29± 885.7
Efficiency (%) 73.35± 4.15 70.37± 17.02 76.22± 6.62 74.06± 5.36
EDV end-diastolic volume, ESV end-systolic volume, SV stroke volume, EF ejection fraction, CO cardiac output, ESP end-systolic pressure, EDP
end-diastolic pressure. Data are expressed as mean± SEM. Two-way ANOVA test followed by post hoc Tukey’s test (*p< 0.005 vs Control, †p<
0.005 vs STZ).
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completely prevented these alterations, suggesting that
hyperglycemia-induced changes in diabetic hearts lead to
enhanced MAO-mediated ROS generation, eventually
prompting cardiac redox imbalance and activation of the
UPR.
MAO activity triggers cardiac fibrosis and mast cell
degranulation in STZ hearts
Cardiac fibrosis is one of the underlying causes of dia-
stolic dysfunction and a major feature of DCM [2, 38].
We observed that STZ-treated hearts displayed 4-fold
increase in collagen deposition as compared to normal
hearts (Fig. 6a, b). Interestingly, pargyline treatment
abrogated this change, demonstrating MAO inhibitors’
ability to prevent fibrosis progression in T1D animals.
Since mast cell degranulation is involved in fibrosis
development and known to play a key role in the
inflammatory process by releasing a number of pro-
inflammatory and pro-fibrotic factors [31, 39], we next
assessed cardiac mast cell density and level of degranu-
lation in STZ vs control mice (Fig. 6c). Although mast
cell density was similar between the groups (Fig. 6d), the
extent of degranulation was markedly higher in STZ mice
Fig. 6 Effects of MAO inhibition on cardiac fibrosis and mast cell
degranulation in STZ-mice. Representative images of Masson’s tri-
chrome staining from control and STZ mice, showing collagen
deposition in blue (a). The quantification data are expressed as per-
centage of fibrotic vs total cardiac tissue (b). Black and white bars
represent vehicle and pargyline treated mice, respectively (Control n
= 10, control+pargyline n= 5, STZ n= 12, STZ+pargyline n= 15).
Representative images of toluidine blue staining of cardiac tissue from
indicated experimental groups (c). Red arrows indicate intact mast
cells, and black arrows indicate actively degranulating mast cells.
Quantification of mast cell density (d) and mast cell degranulation (e).
Results are expressed as number of mast cells per field and percentage
of degranulating mast cells vs total number of mast cells, respectively.
(Control n= 10, control+pargyline n= 5, STZ n= 12, STZ+pargy-
line n= 15). Analysis was carried out by an observer blinded to the
experimental conditions. Data are expressed as mean ± SEM. Two-
way ANOVA test followed by post hoc Tukey’s (d and e) or Dunn’s
(b) multiple comparison test (*p< 0.05 vs control vehicle, #p< 0.05 vs
STZ vehicle)
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(Fig. 6e). Pargyline treatment prevented this event in T1D
mice. Thus, MAO-induced ROS production can trigger
cardiac mast cell activation and degranulation. This
phenomenon, in turn, contributes to the remodeling of the
extracellular matrix, ultimately resulting in LV fibrosis
and dysfunction.
Discussion
The present results demonstrate that MAO-induced ROS
formation causes mitochondrial dysfunction and ER stress,
factors that ultimately promote DCM development (Fig. 7).
The improvement in diastolic stiffness elicited by MAO
inhibition in vivo is accompanied by a reduction in inter-
stitial fibrosis, establishing a previously unappreciated
mechanistic link between cardiac fibrosis and mast cell
degranulation that is MAO-dependent.
Many alterations in cellular and mitochondrial metabo-
lism observed during the development of DCM are asso-
ciated with increased ROS levels. In this setting, cardiac
impairment is not caused by hyperglycemia per se; rather,
oxidative stress and inflammation lead to cardiovascular
complications. Mitochondrial ROS formation and dys-
function lead to the production of IL-1β via the inflamma-
some pathway [33]. In our setting, NLRP3 inflammasome
was hardly activated and occurred independently of MAO-
induced mitochondrial ROS formation. Indeed, HG does
not lead to inflammasome activation in NRVMs [40], sug-
gesting that cardiomyocytes are a target rather than a source
of IL-1β and other inflammatory stimuli produced by other
cells, such as macrophages. Yet, whether and how IL-1β
Fig. 7 Schematic representation of the effects elicited by MAO-
dependent oxidative stress in diabetic cardiomyopathy. Hyperglycemia
and pro-inflammatory stimuli result in enhanced mitochondrial MAO-
dependent H2O2 formation that, in turn, targets mitochondria to induce
mitochondrial dysfunction. These events occur upstream of the
impairment in ER homeostasis and accumulation of unfolded proteins
in the ER lumen. The consequent activation of the UPR through three
ER stress branches, namely IRE1α, PERK and ATF6, leads to protein
translation attenuation, upregulation of chaperones and activation of
ERAD machinery. Moreover, MAO-dependent oxidative stress in vivo
contributes to mast cell degranulation and cardiac fibrosis, ultimately
resulting in diastolic dysfunction in type 1 diabetes. Administration of
the MAO inhibitor pargyline prevents exacerbated ROS formation and
restores mitochondrial and ER homeostasis. In addition, MAO inhi-
bition abolishes mast cell degranulation and fibrosis, thus improving
LV diastolic function. ATF4 activation transcription factor 4, ATF6
activation transcription factor 6, BiP binding immunoglobulin protein,
ER endoplasmic reticulum, ERAD ER associated degradation, eIF2α
eukaryotic initiation factor 2α, IRE1α inositol-requiring enzyme 1α,
IL-1β interleukin 1β, MAO monoamine oxidase, PERK protein kinase
R-like endoplasmic reticulum kinase, ROS reactive oxygen species,
UPR unfolded protein response
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can induce mitochondrial ROS formation has not been
reported. Other studies have shown that diabetes-induced
mitochondrial dysfunction and ROS formation occur
through calpain [41] and O-linked β-N-acetylglucosamine
glycosylation [42]. Here we show that IL-1β, in combina-
tion with HG, induces mitochondrial ROS formation and
dysfunction in a MAO-dependent manner. We further
demonstrate that the opening of the PTP underlies MAO-
induced mitochondrial depolarization. This finding supports
the tight link between oxidative stress and PTP opening and
indicates MAO activity as an upstream event or part of an
amplification pathway exacerbating mitochondrial dys-
function. Future investigations will address whether and
how MAO activity impacts on FOF1 ATPase that has been
recently described as the molecular identity of the PTP [43,
44].
Hyperglycemia and inflammation induce ER stress and
consequently trigger the UPR [40, 45]. Severe and/or pro-
longed ER stress leads to mitochondrial dysfunction,
impaired Ca2+ and redox homeostasis, thus playing a pre-
dominant role in the pathogenesis of multiple cardiovas-
cular diseases [19, 22, 37]. However, the opposite also
holds true. In fact, aberrant ROS formation and alterations
in mitochondrial structure and function may affect ER
homeostasis [36]. Here we show that MAO activity pri-
marily accounts for impaired ER homeostasis and activation
of the UPR. Moreover, HG- and inflammation-induced
ROS formation and mitochondrial dysfunction in cardio-
myocytes occur upstream of ER stress, given that abroga-
tion of MAO-dependent ROS formation was sufficient to
abolish the UPR in those conditions. These findings high-
light a novel role for these flavoenzymes as a key linchpin
between excessive ROS formation and ER stress. In addi-
tion, our present data show that MAO inhibition was not
sufficient to protect cells from damage when ER stress was
induced directly and occurred upstream of mitochondrial
ROS formation. This outcome is likely due to the fact that
both tunicamycin and thapsigargin lead to a more severe ER
stress in comparison to our in vitro diabetic model. On the
other hand, it is plausible that tunicamycin- and
thapsigargin-induced ER stress causes mitochondrial dys-
function, oxidative stress and cell death in a MAO-
independent manner. Indeed, ER stress can induce cell
death as a consequence of SR Ca2+ release and PTP
opening [46].
Another study identified MAO-A as an important
source of ROS in STZ-treated rats, suggesting that its
inhibition may improve cardiac contractility [16]. These
Authors focused on the later stages of DCM, character-
ized by reduced heart rate and contractility, and likely
associated with reduced ejection fraction and dilation.
However, most recent clinical reports on DCM describe a
phenotype that differs from dilated cardiomyopathy [47].
The typical diabetic patient suffering from DCM falls into
the category of heart failure with preserved ejection
fraction (HFpEF), presenting a small LV cavity, normal
systolic LV ejection fraction, thick LV walls, elevated LV
filling pressures and diastolic dysfunction [47]. There-
fore, it is important to assess whether MAOs contribute to
the early impairment in diabetic hearts, represented by
diastolic dysfunction. Here we provide unprecedented
evidence that diastolic stiffness observed in STZ mice is
prevented by MAO inhibition. These findings are of
major clinical relevance because several heart failure
drugs showed positive outcomes in heart failure patients
with reduced ejection fraction, but the outcome was
neutral in HFpEF [47]. Currently, treatment of DCM with
HFpEF phenotype is limited to diuretics and lifestyle
modification. Therefore, our results highlight the ther-
apeutic potential of MAO inhibitors in the latter cohort of
diabetic/HFpEF patients, while providing key mechan-
istic advancement concerning the mechanisms underlying
MAO-induced changes in the diabetic heart. Future stu-
dies must be designed ad hoc to test whether MAO
inhibition affords benefits even when instituted after the
onset of diastolic dysfunction, i.e., at later stages of
DCM.
Collagen deposition and extracellular matrix remodeling
result in the stiffening of the cardiac tissue and diastolic
dysfunction. Mast cell degranulation is a key-contributing
factor in heart failure pathogenesis, irrespective of the
etiology [31]. However, the exact mechanisms leading to
mast cell degranulation are unclear, partly owing to the
multiplicity of environmental stressors they are sensitive to.
Oxidative stress is a trigger for mast cell activation [48], but
until now no study has identified specific ROS source liable
for mast cell degranulation in DCM. Here we report that
MAO activity triggers mast cell degranulation in STZ-mice,
thus providing a mechanistic link between these mito-
chondrial flavoenzymes, inflammation and fibrosis in DCM.
Interestingly, mast cell stabilizer nedocromil has been
shown to only partially prevent structural and functional
changes in the diabetic heart [39]. It is therefore tempting to
hypothesize that the stronger protection observed in our
study is due to the synergistic effects of MAO inhibition on
cardiomyocytes and mast cells. Further studies are neces-
sary to elucidate the exact mechanisms linking MAO acti-
vation and mast cell degranulation.
Besides H2O2 formation, MAOs are also a source of
reactive aldehydes and ammonia [14]. Stimulation of
mitochondrial ALDH2 activity, the enzyme responsible for
aldehyde conversion into the corresponding carboxylic
acids, improves mitochondrial function and reduces cardiac
damage in several models of cardiac injury, including T1D
[49]. It is plausible that MAO inhibition in diabetes abol-
ishes the detrimental effects of these reactive aldehydes as
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well. Another aspect of our study that warrants further, in-
depth investigation is the exact mechanism leading to the
upregulation of MAO activity in diabetes. Although we did
not observe changes in MAO protein expression (Supple-
mentary Figures S3 and S7), increased substrate avail-
ability, post-translational modifications or interactions with
other cellular pathways might account for its increased
activity. In that regard, we have excluded that oxidation
may cause changes in MAO activity (Supplementary Fig-
ure S8). Our data suggest that MAO activity is either absent
or negligible at baseline and becomes relevant only upon
pathological stimuli, most likely when substrate availability
is increased. This is in line with our previous observations
showing that, despite protein levels remained unchanged,
augmented availability and degradation of MAO substrates
norepinephrine and dopamine triggered maladaptive sig-
naling pathways leading to hypertrophy and heart failure in
pressure-overloaded mice [13, 15]. In addition, histamine
has been shown to trigger MAO-dependent impairment in
vasorelaxation [50], although the signaling pathway linking
histamine receptors and/or metabolism with MAO activity
was not elucidated. Considering that histamine, dopamine
and serotonin are all contained in mast cell granules, it is
possible that these substrates are responsible for MAO
activation, at least in this cell type. However, MAOs
degrade many other biogenic amines as well; thus, identi-
fication of substrates responsible for increased MAO
activity in diabetic conditions warrants further investigation
involving a metabolomics approach.
In conclusion, the present findings identify MAOs as
major vehicles of damage during the hyperglycemic and
pro-inflammatory states characterizing DCM. By extension,
MAO inhibitors that are currently used in the clinic for
treating depression or Parkinson’s disease should be con-
sidered as a therapeutic option for diabetes and its com-
plications as well as for other disorders in which mast cell
degranulation is a dominant phenomenon.
Materials and methods
Animals
All animal studies were performed using male C57BL6/J
mice (6–7 weeks of age; Charles River Laboratories, UK).
T1D was induced with STZ intraperitoneally for five con-
secutive days (50 mg/kg/day in citrate buffer pH 4.5).
Animals were then randomized and treated either with
vehicle or MAO inhibitor pargyline (50 mg/kg/day). Blood
glucose levels were measured twice a month using glucose
meter (OneTouch Ultra 2) and mice with blood glucose
levels ≥17 mM were considered diabetic. Animal studies
were performed in accordance with relevant guidelines and
regulations and were approved by the Italian Ministry of
Health and the University of Cambridge.
In vivo cardiac function
In vivo cardiac function was assessed using MRI-calibrated
PV loops. First, a MRI scan was performed as previously
described to assess systolic function [51, 52]. Mice were
quickly anaesthetized with isoflurane followed by a 70mg/kg
intraperitoneal injection of pentobarbital. After endotracheal
intubation for mechanical ventilation (Harvard apparatus,
Holliston, MA), mice underwent closed-chest catheterization
of the left ventricle via the carotid artery. PV data was acquired
using a Transonic ADV 500 system (iWorx 125 Systems Inc.,
NH). Before PV loop analysis, volumes were smoothed
(smoothing kernel of 4ms), and calibrated using the MRI data.
The maximum and minimum volumes obtained with the
catheter were matched to the MRI-derived LV volumes.
Summary pressure and diastolic stiffness values were derived
using Labscribe 2 (iWorx 125 Systems Inc., NH).
Primary myocytes studies
NRVMs were isolated from 1 to 3 days old rats, as previously
described [15] and plated at the density of 100,000 cells/ml in
minimum essential media (MEM) supplemented with FBS
10%, 0.1mM BrdU, antibiotics, and non-essential amino
acids. Cells were maintained at 37°C, 5% CO2. The medium
was changed to MEM supplemented with 1% FBS after 24 h.
Adult mouse ventricular myocytes were isolated from the
hearts of 12 weeks old C57Bl6/J mice, as previously described
[53]. Collagenase-digested isolated myocytes were incubated
in buffer with increasing concentrations of Ca2+, achieving a
final concentration of 1.2mM Ca2+ as in MEM culture media
(Life Technologies). Cells were seeded at 25,000 rod-shaped
myocytes/ml on coverslips coated with laminin. After 1 h
incubation at 37°C, 2% CO2, culture media was replaced to
remove unattached cells.
ROS formation in NRVMs was measured using the
genetically encoded H2O2 sensitive mito-HyPer or cyto-
HyPer plasmids (Evrogen) or 25 nM Mitotracker Red
(MTR, CM-H2XRos, Life Technologies). Cells were
transfected with the calcium phosphate method and
treated for 48 h in following conditions: NG 5 mM, HG
25 mM or HM 25 mM in the presence or absence of 25
ng/ml rat IL-1β (Sigma). To inhibit MAO activity cells
were either pre-treated with 100 µM pargyline (Sigma) or
transfected with scramble or MAO-A siRNA (Ambion).
Adult cardiomyocytes were loaded with 250 nM MTR,
washed and treated as above for 2 h. Images were cap-
tured using fluorescence microscope (Leica). Analysis
and fluorescence intensities were determined using
computer-assisted image analysis systems (ImageJ, NIH).
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To measure ΔΨm, cardiomyocytes were incubated with
NG, HG and IL-1β as above in the absence or presence of
pargyline or CsA (1 µg/ml) for 5 h and then loaded with 25
nM TMRM, a cell-permeant dye sequestered by active
mitochondria, in the presence of 1.6 µM cyclosporin H.
Images were collected using a fluorescence microscope
(Leica) before and after the addition of 6 µM oligomycin (to
NRVMs only) and 2.5 µM FCCP. Images were analyzed
and fluorescence intensities determined using computer-
assisted image analysis systems (ImageJ, NIH). Results are
expressed as ΔF (F0/FFCCP).
To measure oxygen consumption, cells were detached and
permeabilized with 10 µM saponin in the respiration medium
(125mM sucrose, 65mM KCl, 20mM Hepes, 1 mM MgCl2,
200 µM EGTA, 2.5mM KH2PO4). Next, cells were added to
the respiration chamber and basal (state 4) respiration was
monitored following addition of respiration substrates, 5/2.5
mM glutamate/malate (complex I) or 5mM succinate in the
presence of 2 µM rotenone (complex II). After 3min, 1mM
ADP was added to induce state 3 respiration. Data are
expressed as the rate of oxygen consumption normalized to the
number of cells used for the assay.
MAO activity
MAO activity was measured fluorometrically in permeabi-
lized cells in an assay using 10-acetyl-3,7-dihyrdox-
yphenoxazine (Amplex Red reagent, Life Technologies), in
combination with horseradish peroxidase (HRP), to detect
H2O2 generated during substrate catabolism. Following
exposure to H2O2, recombinant MAO-A and –B (Sigma)
were spun down and resuspended in PBS. MAO protein
(3.5 µg/reaction) was diluted in PBS containing 10 µM
Amplex Red and 7.5 µg/ml HRP and added into black
opaque 96-well microplates. Amplex Red fluorescence was
measured kinetically with a fluorescence microplate reader
(Fluoroskan Ascent Microplate fluorometer, Thermo Fisher
Scientific, excitation/emission wavelengths 560/590 nm), at
baseline and following addition of substrates. MAO-A and
-B activities were assayed using tyramine and phenylethy-
lamine as substrates, respectively. The velocity of H2O2
production was calculated from a calibration curve obtained
adding known amounts of H2O2 and results were expressed
as rate of H2O2 formation per µg protein.
Histology
Hearts were fixed in 10% formalin overnight, embedded in
paraffin and sectioned at 5 µm thickness. To detect collagen
deposition, sections were stained with Masson’s Trichrome
(Bio-Optica, Milan, Italy). Photomicrographs of the sections
were evaluated for interstitial collagen fractions using
computer-assisted image analysis systems (Adobe Photoshop).
Metachromatic staining with toluidine blue (0.1%, pH
2.3, for 3 min) was employed to detect mast cell density
and degranulation [31]. Mast cell density was determined
counting the total number of mast cells per field. Mast
cell degranulation was expressed as the number of
degranulating mast cells normalized to total number of
mast cells.
Real time-PCR
Total RNA was extracted from NRVMs using Trizol
reagent (Invitrogen). Isolated RNA was reverse transcribed
to cDNA using random hexamers, dNTPs and SuperScript
III reverse transcriptase (Invitrogen), following manu-
facturer’s protocol and amplified by PCR.
Western blot
Cardiomyocytes or heart tissue were homogenized in lysis
buffer containing protease and phosphatase inhibitors.
Protein concentration was determined using BCA protein
assay (Pierce). Proteins were separated using SDS–PAGE
(Invitrogen) and transferred to nitrocellulose membrane
(Bio-Rad). Following incubation with primary and sec-
ondary HRP-conjugated antibody (Bio-Rad), bands were
detected using KODAK Image station 4000 MM PRO and
analyzed using Gel-Pro software.
Statistical analysis
All values are expressed as mean±SEM. Comparison
between groups was performed by one-way or two-way
ANOVA, followed by Tukey’s post hoc multiple compar-
ison for normally distributed data and non-parametric
Dunn’s test for not normally distributed data. Compar-
isons between two groups were performed using non-paired
two-tailed Student’s t-test. A value of p< 0.05 was con-
sidered significant.
Acknowledgements We thank Drs. Graeme Eisenhofer, Luca Scor-
rano, Tatiana Varanita and Suresh Palaniyandi for helpful discus-
sion and advice. This work was supported by the EFSD/Sanofi
research grant (NK), Leducq Transatlantic Network of Excellence,
MIUR and University of Padova Strategico grant (FDL), CNR (NK
and FDL), Medical Research Council UK (MC_U105663142), and
Wellcome Trust Investigator award (110159/Z/15/Z to MPM).
DMR was supported by NIH (HL52141). NK and MDS are Fellows
of the Leducq Transatlantic Networks of Excellence. SD and MF
were supported by the Marie Sklodowska Curie fellowship through
the RADOX ITN network.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
MAO, ER stress and diabetic cardiomyopathy
Official journal of the Cell Death Differentiation Association
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard
BV, et al. Diabetes and cardiovascular disease: a statement for
healthcare professionals from the American Heart Association.
Circulation. 1999;100:1134–46.
2. Bugger H, Abel ED. Molecular mechanisms of diabetic cardio-
myopathy. Diabetologia. 2014;57:660–71.
3. Baseler WA, Dabkowski ER, Jagannathan R, Thapa D, Nichols
CE, Shepherd DL, et al. Reversal of mitochondrial proteomic loss
in Type 1 diabetic heart with overexpression of phospholipid
hydroperoxide glutathione peroxidase. Am J Physiol Regul Integr
Comp Physiol. 2013;304:R553–65.
4. Matsushima S, Kinugawa S, Ide T, Matsusaka H, Inoue N, Ohta
Y, et al. Overexpression of glutathione peroxidase attenuates
myocardial remodeling and preserves diastolic function in
diabetic heart. Am J Physiol Heart Circ Physiol. 2006;291:
H2237–45.
5. Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC, et al.
Catalase protects cardiomyocyte function in models of type 1 and
type 2 diabetes. Diabetes. 2004;53:1336–43.
6. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac
mitochondria by overexpression of MnSOD reduces diabetic
cardiomyopathy. Diabetes. 2006;55:798–805.
7. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and
effects. Rev Endocr Metab Disord. 2010;11:31–39.
8. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T,
Kaneda Y, et al. Normalizing mitochondrial superoxide produc-
tion blocks three pathways of hyperglycaemic damage. Nature.
2000;404:787–90.
9. Di Lisa F, Giorgio M, Ferdinandy P, Schulz R. New aspects of
p66Shc in ischaemia reperfusion injury and other cardiovascular
diseases. Br J Pharmacol. 2017;174:1690–703.
10. Shen E, Li Y, Li Y, Shan L, Zhu H, Feng Q, et al. Rac1 is required
for cardiomyocyte apoptosis during hyperglycemia. Diabetes.
2009;58:2386–95.
11. Dabkowski ER, Williamson CL, Bukowski VC, Chapman RS,
Leonard SS, Peer CJ, et al. Diabetic cardiomyopathy-associated
dysfunction in spatially distinct mitochondrial subpopulations.
Am J Physiol Heart Circ Physiol. 2009;296:H359–69.
12. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX,
et al. Mitochondrial energetics in the heart in obesity-related
diabetes: direct evidence for increased uncoupled respiration and
activation of uncoupling proteins. Diabetes. 2007;56:2457–66.
13. Kaludercic N, Carpi A, Nagayama T, Sivakumaran V, Zhu G, Lai
EW, et al. Monoamine oxidase B prompts mitochondrial and
cardiac dysfunction in pressure overloaded hearts. Antioxid
Redox Signal. 2014;20:267–80.
14. Kaludercic N, Mialet-Perez J, Paolocci N, Parini A, Di Lisa F.
Monoamine oxidases as sources of oxidants in the heart. J Mol
Cell Cardiol. 2014;73:34–42.
15. Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja
D, et al. Monoamine oxidase A-mediated enhanced catabolism of
norepinephrine contributes to adverse remodeling and pump
failure in hearts with pressure overload. Circ Res.
2010;106:193–202.
16. Umbarkar P, Singh S, Arkat S, Bodhankar SL, Lohidasan S,
Sitasawad SL. Monoamine oxidase-A is an important source of
oxidative stress and promotes cardiac dysfunction, apoptosis, and
fibrosis in diabetic cardiomyopathy. Free Radic Biol Med.
2015;87:263–73.
17. Binda C, Newton-Vinson P, Hubalek F, Edmondson DE,
Mattevi A. Structure of human monoamine oxidase B, a drug
target for the treatment of neurological disorders. Nat Struct
Biol. 2002;9:22–6.
18. Son SY, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara
T. Structure of human monoamine oxidase A at 2.2-A resolution:
the control of opening the entry for substrates/inhibitors. Proc Natl
Acad Sci USA. 2008;105:5739–44.
19. Groenendyk J, Sreenivasaiah PK, Kim DH, Agellon LB, Michalak
M. Biology of endoplasmic reticulum stress in the heart. Circ Res.
2010;107:1185–97.
20. Miki T, Miura T, Hotta H, Tanno M, Yano T, Sato T, et al.
Endoplasmic reticulum stress in diabetic hearts abolishes
erythropoietin-induced myocardial protection by impairment of
phospho-glycogen synthase kinase-3beta-mediated suppression of
mitochondrial permeability transition. Diabetes.
2009;58:2863–72.
21. Yang L, Zhao D, Ren J, Yang J. Endoplasmic reticulum stress and
protein quality control in diabetic cardiomyopathy. Biochim
Biophys Acta. 2015;1852:209–18.
22. Arruda AP, Pers BM, Parlakgul G, Guney E, Inouye K, Hota-
misligil GS. Chronic enrichment of hepatic endoplasmic
reticulum-mitochondria contact leads to mitochondrial dysfunc-
tion in obesity. Nat Med. 2014;20:1427–35.
23. Dorn GW 2nd, Song M, Walsh K. Functional implications of
mitofusin 2-mediated mitochondrial-SR tethering. J Mol Cell
Cardiol. 2015;78:123–8.
24. de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reti-
culum to mitochondria. Nature. 2008;456:605–10.
25. Lewis SC, Uchiyama LF, Nunnari J. ER-mitochondria contacts
couple mtDNA synthesis with mitochondrial division in human
cells. Science. 2016;353:aaf5549.
26. Sebastian D, Hernandez-Alvarez MI, Segales J, Sorianello E,
Munoz JP, Sala D, et al. Mitofusin 2 (Mfn2) links mitochondrial
and endoplasmic reticulum function with insulin signaling and is
essential for normal glucose homeostasis. Proc Natl Acad Sci
USA. 2012;109:5523–8.
27. Lafuente N, Matesanz N, Azcutia V, Romacho T, Nevado J,
Rodriguez-Manas L, et al. The deleterious effect of high con-
centrations of D-glucose requires pro-inflammatory pre-
conditioning. J Hypertens. 2008;26:478–85.
28. Kanasaki K, Taduri G, Koya D. Diabetic nephropathy: the role of
inflammation in fibroblast activation and kidney fibrosis. Front
Endocrinol. 2013;4:7.
29. Richter K, Kietzmann T. Reactive oxygen species and fibrosis:
further evidence of a significant liaison. Cell Tissue Res.
2016;365:591–605.
30. Levick SP, Melendez GC, Plante E, McLarty JL, Brower GL,
Janicki JS. Cardiac mast cells: the centrepiece in adverse myo-
cardial remodelling. Cardiovasc Res. 2011;89:12–19.
31. Palaniyandi SS, Inagaki K, Mochly-Rosen D. Mast cells and
epsilonPKC: a role in cardiac remodeling in hypertension-induced
heart failure. J Mol Cell Cardiol. 2008;45:779–86.
32. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert
B, et al. Interleukin-1-receptor antagonist in type 2 diabetes
mellitus. N Engl J Med. 2007;356:1517–26.
S. Deshwal et al.
Official journal of the Cell Death Differentiation Association
33. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in
NLRP3 inflammasome activation. Nature. 2011;469:221–5.
34. Irwin WA, Bergamin N, Sabatelli P, Reggiani C, Megighian A,
Merlini L, et al. Mitochondrial dysfunction and apoptosis in
myopathic mice with collagen VI deficiency. Nat Genet.
2003;35:367–71.
35. Rasola A, Bernardi P. The mitochondrial permeability transition
pore and its adaptive responses in tumor cells. Cell Calcium.
2014;56:437–45.
36. Malhotra JD, Miao H, Zhang K, Wolfson A, Pennathur S, Pipe SW,
et al. Antioxidants reduce endoplasmic reticulum stress and improve
protein secretion. Proc Natl Acad Sci USA. 2008;105:18525–30.
37. Safiedeen Z, Rodriguez-Gomez I, Vergori L, Soleti R, Vaithi-
lingam D, Douma I, et al. Temporal cross talk between endo-
plasmic reticulum and mitochondria regulates oxidative stress and
mediates microparticle-induced endothelial dysfunction. Antioxid
Redox Signal. 2017;26:15–27.
38. Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy:
pathophysiology and clinical features. Heart Fail Rev.
2013;18:149–66.
39. Huang ZG, Jin Q, Fan M, Cong XL, Han SF, Gao H, et al.
Myocardial remodeling in diabetic cardiomyopathy associated
with cardiac mast cell activation. PLoS ONE. 2013;8:e60827.
40. Liu Z, Zhao N, Zhu H, Zhu S, Pan S, Xu J, et al. Circulating
interleukin-1beta promotes endoplasmic reticulum stress-
induced myocytes apoptosis in diabetic cardiomyopathy via
interleukin-1 receptor-associated kinase-2. Cardiovasc Diabe-
tol. 2015;14:125.
41. Ni R, Zheng D, Xiong S, Hill DJ, Sun T, Gardiner RB. et al.
Mitochondrial calpain-1 disrupts ATP synthase and induces
superoxide generation in type 1 diabetic hearts: a novel
mechanism contributing to diabetic cardiomyopathy. Diabetes.
2016;65:255–68.
42. Hu Y, Suarez J, Fricovsky E, Wang H, Scott BT, Trauger SA,
et al. Increased enzymatic O-GlcNAcylation of mitochondrial
proteins impairs mitochondrial function in cardiac myocytes
exposed to high glucose. J Biol Chem. 2009;284:547–55.
43. Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari F,
Forte M, et al. Dimers of mitochondrial ATP synthase form the
permeability transition pore. Proc Natl Acad Sci USA.
2013;110:5887–92.
44. Kaludercic N, Giorgio V. The dual function of reactive oxygen/
nitrogen species in bioenergetics and cell death: the Role of ATP
synthase. Oxid Med Cell Longev. 2016;2016:3869610.
45. Hotamisligil GS. Endoplasmic reticulum stress and the inflam-
matory basis of metabolic disease. Cell. 2010;140:900–17.
46. Lee GH, Lee HY, Li B, Kim HR, Chae HJ. Bax inhibitor-1-
mediated inhibition of mitochondrial Ca2+ intake regulates mito-
chondrial permeability transition pore opening and cell death. Sci
Rep. 2014;4:5194.
47. Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a
two-faced disease with restrictive and dilated phenotypes. Eur
Heart J. 2015;36:1718–27.
48. Koda K, Salazar-Rodriguez M, Corti F, Chan NY, Estephan R,
Silver RB, et al. Aldehyde dehydrogenase activation prevents
reperfusion arrhythmias by inhibiting local renin release from
cardiac mast cells. Circulation. 2010;122:771–81.
49. Zhang Y, Babcock SA, Hu N, Maris JR, Wang H, Ren J. Mito-
chondrial aldehyde dehydrogenase (ALDH2) protects against
streptozotocin-induced diabetic cardiomyopathy: role of
GSK3beta and mitochondrial function. BMC Med. 2012;10:40.
50. Sturza A, Leisegang MS, Babelova A, Schroder K, Benkhoff S,
Loot AE, et al. Monoamine oxidases are mediators of endothelial
dysfunction in the mouse aorta. Hypertension. 2013;62:
140–6.
51. Buonincontri G, Methner C, Carpenter TA, Hawkes RC, Sawiak
SJ. Krieg TMRI and PET in mouse models of myocardial
infarction. J Vis Exp. 2013;82:e50806.
52. Buonincontri G, Methner C, Krieg T, Carpenter TA, Sawiak SJ.
Functional assessment of the mouse heart by MRI with a 1-min
acquisition. NMR Biomed. 2014;27:733–7.
53. O’Connell TD, Rodrigo MC, Simpson PC. Isolation and culture of
adult mouse cardiac myocytes. Methods Mol Biol.
2007;357:271–96.
MAO, ER stress and diabetic cardiomyopathy
Official journal of the Cell Death Differentiation Association
